

Raphaelle Seror

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039992/publications.pdf>

Version: 2024-02-01

179
papers

14,272
citations

38742
50
h-index

20961
115
g-index

187
all docs

187
docs citations

187
times ranked

10679
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. <i>Arthritis and Rheumatology</i> , 2017, 69, 35-45.	5.6	993
2	2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 9-16.	0.9	959
3	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	27.0	842
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
5	EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1103-1109.	0.9	734
6	The Five-Factor Score Revisited. <i>Medicine (United States)</i> , 2011, 90, 19-27.	1.0	716
7	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 270-281.	6.7	670
8	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. <i>Arthritis and Rheumatism</i> , 2010, 62, 616-626.	6.7	483
9	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
10	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
11	Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 351-357.	0.9	261
12	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
13	Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 526-531.	0.9	248
14	Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 249.	7.4	241
15	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
16	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
17	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	1.9	220
18	Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2074-2081.	0.9	204

#	ARTICLE	IF	CITATIONS
19	Central Nervous System Involvement in Wegener Granulomatosis. <i>Medicine (United States)</i> , 2006, 85, 53-65.	1.0	197
20	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193
21	High frequency of venous thromboembolic events in Churgâ€“Strauss syndrome, Wegenerâ€™s granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 564-567.	0.9	184
22	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
23	Reporting of results from network meta-analyses: methodological systematic review. <i>BMJ, The</i> , 2014, 348, g1741-g1741.	6.0	149
24	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012, 51, 460-467.	1.9	147
25	Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögrenâ€™s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort. <i>PLoS ONE</i> , 2013, 8, e59868.	2.5	147
26	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 977-985.	5.6	146
27	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1042-1050.	0.9	132
28	Rationale and efficacy of interleukin-1 targeting in Erdheimâ€“Chester disease. <i>Blood</i> , 2010, 116, 4070-4076.	1.4	129
29	Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses. <i>Journal of Rheumatology</i> , 2014, 41, 194-205.	2.0	124
30	Pattern of demyelination occurring during anti-TNF-Î± therapy: a French national survey. <i>Rheumatology</i> , 2013, 52, 868-874.	1.9	120
31	Early diagnosis of primary Sjögrenâ€™s syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 137-156.	3.0	118
32	Ophthalmologic Manifestations of Systemic Necrotizing Vasculitides at Diagnosis: A Retrospective Study of 1286 Patients and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 507-514.	3.4	112
33	Epidemiology of Primary Sjögren's Syndrome in a French Multiracial/Multiethnic Area. <i>Arthritis Care and Research</i> , 2014, 66, 454-463.	3.4	107
34	Meralgia paresthetica: Clinical and electrophysiological diagnosis in 120 cases. <i>Muscle and Nerve</i> , 2006, 33, 650-654.	2.2	94
35	Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. <i>Arthritis Care and Research</i> , 2011, 63, 277-285.	3.4	94
36	Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 476-478.	0.9	90

#	ARTICLE	IF	CITATIONS
37	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. <i>Rheumatology</i> , 2015, 54, 424-432.	1.9	89
38	Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2747-2754.	6.7	87
39	Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. <i>BMJ</i> , The, 2013, 347, f3675-f3675.	6.0	85
40	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77
41	CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2015, 67, 3226-3233.	5.6	74
42	European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2013, 65, 1358-1364.	3.4	71
43	Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. <i>Arthritis Care and Research</i> , 2010, 62, 551-558.	3.4	66
44	Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study. <i>Rheumatology</i> , 2015, 54, kev257.	1.9	66
45	Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial. <i>Arthritis Care and Research</i> , 2017, 69, 528-535.	3.4	65
46	Current and future therapies for primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2021, 17, 475-486.	8.0	64
47	Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 339-348.	0.9	63
48	Association of Anti- <i>Porphyromonas gingivalis</i> Antibody Titers With Nonsmoking Status in Early Rheumatoid Arthritis: Results From the Prospective French Cohort of Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1729-1737.	5.6	61
49	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 329-338.	0.9	61
50	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1945-1950.	0.9	57
51	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020, 59, 2350-2359.	1.9	54
52	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019, 5, e001064.	3.8	53
53	Measure of function in rheumatoid arthritis: individualised or classical scales?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 97-101.	0.9	52
54	Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2022, 74, 927-933.	5.6	52

#	ARTICLE	IF	CITATIONS
55	Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort. <i>Scientific Reports</i> , 2016, 6, 18421.	3.3	51
56	Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. <i>Rheumatology</i> , 2015, 54, 1699-1708.	1.9	49
57	Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors. <i>Journal of Immunology</i> , 2019, 203, 1766-1775.	0.8	49
58	Outcome measures for primary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 2012, 39, 97-102.	6.5	46
59	Role of Fms-like Tyrosine Kinase 3 Ligand as a Potential Biologic Marker of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatism</i> , 2013, 65, 3218-3227.	6.7	46
60	Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2125-2130.	0.9	45
61	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
62	Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection. <i>Rheumatology</i> , 2018, 57, 538-547.	1.9	43
63	Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporosis International</i> , 2019, 30, 221-229.	3.1	43
64	ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?. <i>RMD Open</i> , 2015, 1, e000066-e000066.	3.8	41
65	Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study. <i>Arthritis Research and Therapy</i> , 2015, 17, 241.	3.5	40
66	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 780-783.	0.9	40
67	2020 French recommendations on the management of septic arthritis in an adult native joint. <i>Joint Bone Spine</i> , 2020, 87, 538-547.	1.6	40
68	Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016, 68, 1245-1250.	5.6	39
69	Passive smoking in childhood increases the risk of developing rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1154-1162.	1.9	39
70	A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren's syndrome. <i>Rheumatology</i> , 2017, 56, kew376.	1.9	38
71	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 112, 102-112.	0.8	37
72	Dietary recommendations of the French Society for Rheumatology for patients with chronic inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2022, 89, 105319.	1.6	35

#	ARTICLE	IF	CITATIONS
73	Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. Journal of Allergy and Clinical Immunology, 2018, 142, 258-268.e5.	2.9	34
74	Upregulation of Membrane-Bound CD_{40L} on CD_4^{+} T cells in Women with Primary Sjögren's Syndrome. Scandinavian Journal of Immunology, 2014, 79, 37-42.	2.7	32
75	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
76	Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study. Autoimmunity Reviews, 2019, 18, 9-14.	5.8	32
77	Usefulness of ^{18}F -labeled Fluorodeoxyglucose-Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2019, 71, 1147-1157.	5.6	30
78	Mediterranean Diet and Risk of Rheumatoid Arthritis: Findings From the French E3N-EPIC Cohort Study. Arthritis and Rheumatology, 2021, 73, 69-77.	5.6	30
79	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. European Journal of Internal Medicine, 2018, 57, 96-104.	2.2	29
80	Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry. Lancet Rheumatology, The, 2022, 4, e8-e11.	3.9	29
81	Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy. Rheumatology, 2020, 59, 1347-1354.	1.9	28
82	Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome. Annals of the Rheumatic Diseases, 2022, 81, 979-989.	0.9	27
83	Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis and Rheumatology, 2021, 73, 631-640.	5.6	26
84	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. PLoS ONE, 2015, 10, e0134974.	2.5	26
85	Anti-RNP positivity in primary Sjögren's syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. RMD Open, 2019, 5, e001033.	3.8	25
86	Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls. Journal of Hematology and Oncology, 2021, 14, 166.	17.0	24
87	Use of Biologics in Sjögren's Syndrome. Rheumatic Disease Clinics of North America, 2016, 42, 407-417.	1.9	23
88	Environment and Lifestyle: Their Influence on the Risk of RA. Journal of Clinical Medicine, 2020, 9, 3109.	2.4	23
89	Malignancy and the Risks of Biologic Therapies. Rheumatic Disease Clinics of North America, 2017, 43, 43-64.	1.9	22
90	Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit. Journal of Bone and Mineral Research, 2018, 33, 540-542.	2.8	22

#	ARTICLE	IF	CITATIONS
91	Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. <i>Rheumatology</i> , 2021, 60, 675-681.	1.9	21
92	Update of Strategies to Translate Evidence from Cochrane Musculoskeletal Group Systematic Reviews for Use by Various Audiences. <i>Journal of Rheumatology</i> , 2014, 41, 206-215.	2.0	19
93	Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?. <i>PLoS ONE</i> , 2015, 10, e0133907.	2.5	19
94	Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. <i>Lupus</i> , 2016, 25, 1440-1447.	1.6	19
95	New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e122-e122.	0.9	19
96	Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1480-1481.	0.9	18
97	Increase In IL-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. <i>Scientific Reports</i> , 2018, 8, 7731.	3.3	17
98	Improving accuracy of self-reported diagnoses of rheumatoid arthritis in the French prospective E3N-EPIC cohort: a validation study. <i>BMJ Open</i> , 2019, 9, e033536.	1.9	17
99	Chronic diarrhoea and risk of rheumatoid arthritis: findings from the French E3N-EPIC Cohort Study. <i>Rheumatology</i> , 2020, 59, 3767-3775.	1.9	16
100	Efficacy of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1257-1259.	0.9	16
101	Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study. <i>Rheumatology</i> , 2021, 60, 4790-4800.	1.9	16
102	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 681-688.	3.4	15
103	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. <i>Journal of Rheumatology</i> , 2017, 44, 1011-1017.	2.0	15
104	SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients. <i>Rheumatology</i> , 2021, 60, 2946-2957.	1.9	15
105	Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional impairment in hip or knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 494-499.	0.9	14
106	Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies. <i>Muscle and Nerve</i> , 2020, 61, 515-520.	2.2	14
107	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021, 41, 1593-1600.	3.0	13
108	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. <i>RMD Open</i> , 2021, 7, e001698.	3.8	13

#	ARTICLE	IF	CITATIONS
109	Progressive osseous heteroplasia: a rare case of late onset. <i>Rheumatology</i> , 2006, 46, 716-717.	1.9	12
110	OP0217â€¦Defining Disease Activity Sates and Minimal Clinically Important Improvement (MCII) with the EULAR Primary Sj�gren's Syndrome Disease Activity Index (ESSDAI). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 144.2-145.	0.9	12
111	Rituximab�Bendamustine (R�Benda) in <scp>MALT</scp> lymphoma complicating primary Sj�gren syndrome (<scp>pSS</scp>). <i>British Journal of Haematology</i> , 2019, 184, 472-475.	2.5	12
112	Epidemiology of cutaneous involvement in Sj�gren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS). <i>Joint Bone Spine</i> , 2021, 88, 105162.	1.6	12
113	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. <i>Rheumatology</i> , 2022, 62, 243-255.	1.9	12
114	Influence of the age at diagnosis in the disease expression of primary Sj�gren syndrome. Analysis of 12,753 patients from the Sj�gren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 166-174.	0.8	12
115	Prevalence of obesity and obesity as a risk factor in patients with severe median nerve lesion at the wrist. <i>Joint Bone Spine</i> , 2013, 80, 632-637.	1.6	11
116	Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses. <i>RMD Open</i> , 2022, 8, e002308.	3.8	11
117	Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Oencia in Rheumatoid Arthritis Registry. <i>Rheumatology</i> , 2017, 56, kew476.	1.9	10
118	Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. <i>Rheumatology</i> , 2020, 59, 3275-3283.	1.9	10
119	Efficacy and safety of rituximab in peripheral ulcerative keratitis associated with rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001472.	3.8	10
120	Plasma exchange for rheumatoid arthritis. <i>Transfusion and Apheresis Science</i> , 2007, 36, 195-199.	1.0	9
121	Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. <i>Joint Bone Spine</i> , 2010, 77, 604-607.	1.6	9
122	Hand workload, computer use and risk of severe median nerve lesions at the wrist. <i>Rheumatology</i> , 2012, 51, 362-367.	1.9	8
123	Primary Sj�gren's Syndrome Prevalence: What if Sj�gren was Right After All? Comment on the Article by Maciel et al. <i>Arthritis Care and Research</i> , 2018, 70, 951-953.	3.4	8
124	Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). <i>Joint Bone Spine</i> , 2019, 86, eS2-eS103.	1.6	8
125	Seasonal effect on fatigue, pain and dryness in primary Sj�gren���� syndrome. <i>Arthritis Research and Therapy</i> , 2020, 22, 39.	3.5	8
126	Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?. <i>Rheumatology</i> , 2021, 60, 5413-5418.	1.9	8

#	ARTICLE	IF	CITATIONS
127	Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients. <i>Rheumatology</i> , 2022, 61, 3818-3823.	1.9	8
128	Severe deafness associated with Crohn's disease and spondylarthropathy: successful treatment with anti-TNF. <i>Rheumatology</i> , 2013, 52, 1145-1147.	1.9	7
129	New biological therapies in Sjögren's syndrome. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 783-793.	3.3	7
130	Orbital Myositis and Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2015, 42, 1536-1537.	2.0	7
131	Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1835-1836.	0.9	7
132	Disease activity and patient reported outcome measures in Sjögren's – what are the best tools to evaluate?. <i>Rheumatology</i> , 2019, , .	1.9	7
133	Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016–2017. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1612-1621.	0.9	7
134	Outcome Measures in Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020, 72, 134-149.	3.4	6
135	Characteristics of Sjögren's syndrome associated with rheumatoid arthritis. <i>RMD Open</i> , 2022, 8, e002234.	3.8	6
136	Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. <i>RMD Open</i> , 2022, 8, e002139.	3.8	6
137	Reporting of corticosteroid use in systemic disease trials: Evidence from a systematic review of the potential impact on treatment effect. <i>Arthritis Care and Research</i> , 2010, 62, 1002-1008.	3.4	5
138	Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e3-e3.	0.9	5
139	Denosumab in active Charcot neuro-osteoarthropathy of the foot. <i>Joint Bone Spine</i> , 2021, 88, 105241.	1.6	5
140	Fish Consumption and Risk of Rheumatoid Arthritis: Findings from the E3N Cohort Study. <i>Nutrients</i> , 2022, 14, 861.	4.1	5
141	Passive smoking in childhood and adulthood and risk of rheumatoid arthritis in women: results from the French E3N cohort study. <i>RMD Open</i> , 2022, 8, e001980.	3.8	5
142	Severe and extreme idiopathic median nerve lesions at the wrist: New insights into electrodiagnostic patterns and review of the literature. <i>Muscle and Nerve</i> , 2015, 51, 201-206.	2.2	4
143	Cost-effectiveness of rituximab strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017, 389, 365-366.	13.7	4
144	Guidelines for treatment of primary Sjögren's syndrome: a first useful stone but still much to do. <i>Rheumatology</i> , 2017, 56, 1641-1642.	1.9	4

#	ARTICLE	IF	CITATIONS
145	Correspondence on "Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort". Annals of the Rheumatic Diseases, 2023, 82, e32-e32.	0.9	4
146	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. Drugs and Aging, 2021, 38, 265-284.	2.7	4
147	IgG4-related disease associated with renal microaneurysms and polycythaemia. Rheumatology, 2016, 55, 380-382.	1.9	3
148	Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care. Journal of Clinical Epidemiology, 2016, 69, 235-244.	5.0	3
149	Reply. Arthritis and Rheumatology, 2017, 69, 1342-1342.	5.6	3
150	SP0190...2019 EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SJÖGREN'S SYNDROME WITH TOPICAL AND SYSTEMIC THERAPIES. , 2019, , .		3
151	Lifetime female hormonal exposure and risk of rheumatoid arthritis in postmenopausal women: Results from the French E3N cohort. Joint Bone Spine, 2022, 89, 105374.	1.6	3
152	Cervical syphilitic spondylodiscitis associated with neurosyphilis. Rheumatology, 2011, 50, 1723-1725.	1.9	2
153	18F-FDG PET/CT of extensive rheumatoid nodulosis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2333-2334.	6.4	2
154	Large granular lymphocyte expansions in primary Sjögren's syndrome: characteristics and outcomes. RMD Open, 2019, 5, e001044.	3.8	2
155	Inflammation-targeted therapies and cancer. Joint Bone Spine, 2021, 88, 105176.	1.6	2
156	Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry. Joint Bone Spine, 2022, 89, 105310.	1.6	2
157	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
158	Associations between ocular and extra-ocular assessment in primary Sjögren's syndrome*. Joint Bone Spine, 2022, 89, 105426.	1.6	2
159	Is miR200b-5p a new predictor of lymphoma or associated with lymphocytes infiltrate within salivary glands?. Annals of the Rheumatic Diseases, 2019, 78, e95-e95.	0.9	1
160	Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF. RMD Open, 2022, 8, e001697.	3.8	1
161	Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma. Joint Bone Spine, 2022, 89, 105390.	1.6	1
162	Excessive FMS-like tyrosine kinase3-ligand heralds lymphoma in primary sjogren's syndrome. Annals of the Rheumatic Diseases, 2011, 70, A59-A59.	0.9	0

#	ARTICLE	IF	CITATIONS
163	THU0264â€¦In Early Rheumatoid Arthritis (Espoir Cohort), Serum CCL19 Level is Associated with Disease Activity, Autoantibody Secretion and 3-Year Radiographic Progression: Data from the Espoir Cohort. Annals of the Rheumatic Diseases, 2014, 73, 274.2-274.	0.9	0
164	SP0068â€¦Developing Indices for SjÃ¶gren's Syndrome. Annals of the Rheumatic Diseases, 2014, 73, 18.4-19.	0.9	0
165	OP0218â€¦Elevated Serum BAFF is Associated with an Increased Risk of Developing A New Systemic Complication: Data from the Prospective ASSESS Cohort. Annals of the Rheumatic Diseases, 2014, 73, 145.1-145.	0.9	0
166	Reply. Arthritis and Rheumatology, 2015, 67, 3330-3330.	5.6	0
167	Reply. Arthritis and Rheumatology, 2016, 68, 1319-1320.	5.6	0
168	O8â€¦Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
169	Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice. Clinical and Experimental Immunology, 2021, 205, 169-181.	2.6	0
170	Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine, 2021, 88, 105174.	1.6	0
171	Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al. Arthritis Care and Research, 2022, 74, 162-162.	3.4	0
172	Looking into the Futureâ€”The EULAR Disease Activity Scores: Toward a Consensual Evaluation of Primary Sjogrenâ€™s Syndrome. , 2011, , 443-454.		0
173	Lymphoma complicating rheumatoid arthritis: results from a French case-control study. RMD Open, 2021, 7, .	3.8	0
174	Plasma cell gingivitis, an underestimated condition in patients with SjÃ¶gren's syndrome?. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
175	Post-COVID-19 syndrome in patients with primary SjÃ¶gren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
176	Anthropometric Measures and Risk of Rheumatoid Arthritis in the French E3N Cohort Study. Nutrients, 2022, 14, 934.	4.1	0
177	Plasma cell gingivitis, an underestimated condition in patients with SjÃ¶gren's syndrome?. Clinical and Experimental Rheumatology, 2021, 39, 225-225.	0.8	0
178	Concomitant fibromyalgia in primary SjÃ¶gren's syndrome in the French ASSESS cohort: comparison of the ACR 1990 and ACR 2016 criteria, FIRST questionnaire and physician's opinion.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 140-145.	0.8	0
179	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0